Question · asked by 1 review

160/4.5 mcg BDF single inhaler therapy vs current best practice: Hospital admissions due to exacerbations: number of participants

160/4.5 mcg BDF single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with current best practice (low certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
160/4.5 mcg BDF single inhaler therapy vs current best practice
Patients with exacerbations causing hospitalisation · adults with asthma that is not controlled on ICS
160/4.5 mcg BDF single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with current best practice (low certainty).
Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice… (2013) · Cochrane Headline outcomes only
OR 0.81 [0.45, 1.44]8 studies · 8841 participantsLow

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid…
2013 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.